ATE203274T1 - Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten - Google Patents

Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten

Info

Publication number
ATE203274T1
ATE203274T1 AT95908666T AT95908666T ATE203274T1 AT E203274 T1 ATE203274 T1 AT E203274T1 AT 95908666 T AT95908666 T AT 95908666T AT 95908666 T AT95908666 T AT 95908666T AT E203274 T1 ATE203274 T1 AT E203274T1
Authority
AT
Austria
Prior art keywords
nonantibody
fusion protein
domain
growth factor
antibody parts
Prior art date
Application number
AT95908666T
Other languages
English (en)
Inventor
William J Larochelle
Stuart A Aaronson
Olaf Dirsch
Original Assignee
Nasa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nasa filed Critical Nasa
Application granted granted Critical
Publication of ATE203274T1 publication Critical patent/ATE203274T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95908666T 1994-02-01 1995-02-01 Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten ATE203274T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18955294A 1994-02-01 1994-02-01
PCT/US1995/000974 WO1995021258A1 (en) 1994-02-01 1995-02-01 Fusion proteins that include antibody and nonantibody portions

Publications (1)

Publication Number Publication Date
ATE203274T1 true ATE203274T1 (de) 2001-08-15

Family

ID=22697828

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95908666T ATE203274T1 (de) 1994-02-01 1995-02-01 Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten

Country Status (8)

Country Link
US (1) US6403769B1 (de)
EP (1) EP0742830B1 (de)
JP (1) JPH09509054A (de)
AT (1) ATE203274T1 (de)
AU (1) AU689214B2 (de)
CA (1) CA2182498A1 (de)
DE (1) DE69521789T2 (de)
WO (1) WO1995021258A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
FR2746815A1 (fr) * 1996-03-26 1997-10-03 Pasteur Institut Sequences en amont du gene sm 22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
ES2218666T3 (es) * 1996-10-15 2004-11-16 Amgen Inc., Producto a base del factor de crecimiento de queratinocitos-2 (kggf-2).
US6887475B1 (en) 1996-11-07 2005-05-03 Lorantis Limited Notch
CN1524583A (zh) * 1996-11-07 2004-09-01 能够表达Notch-配体的基因在制备用于免疫治疗的药物中的应用
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US5998598A (en) * 1997-03-10 1999-12-07 The United States Of America, As Represented By The Department Of Health And Human Services Immunoadhesins and methods of production and use thereof
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
EP2241623A3 (de) 1999-07-07 2010-12-01 ZymoGenetics, Inc. Monoklonaler Antikörper gegen menschlichen Cytokinrezeptor
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
KR20030064275A (ko) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
ES2329012T3 (es) 2000-11-07 2009-11-20 Zymogenetics, Inc. Receptor del factor de necrosis tumoral humano.
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (de) 2001-05-03 2011-03-16 Merck Patent GmbH Rekombinanter, tumorspezifischer antikörper und dessen verwendung
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
AU2002337920A1 (en) * 2001-10-19 2003-04-28 Zymogenetics, Inc. Dimerized growth factor and materials and methods for producing it
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
WO2004035537A2 (en) 2002-10-16 2004-04-29 Euro-Celtique S.A. Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
JP2007525438A (ja) 2003-03-24 2007-09-06 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
JP2007501021A (ja) * 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
EP1702069A2 (de) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Auf onkofötales fibronectin gerichtetes interleukin-12
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
EP1856156A2 (de) 2005-02-08 2007-11-21 ZymoGenetics, Inc. Anti-il-20-, anti-il-22- und anti-il-22ra-antikörper und bindungspartner sowie verwendungsverfahren bei entzündungen
EP1891107B1 (de) 2005-05-12 2011-07-06 ZymoGenetics, Inc. Zusammensetzungen und verfahren zur modulierung von immunreaktionen
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
WO2009065415A1 (en) 2007-11-21 2009-05-28 Roskilde Universitet Polypeptides comprising an ice-binding activity
KR101720760B1 (ko) 2008-01-25 2017-03-28 오르후스 우니베르시테트 Ｉｇｆｂｐ-4에 대한 ｐａｐｐ-ａ 활성의 선택적 엑소사이트 억제
RU2531754C2 (ru) * 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
PL3552619T3 (pl) 2010-07-09 2025-12-01 Bioverativ Therapeutics Inc. Polipeptydy czynnika ix i sposoby ich zastosowania
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
EP2900265B1 (de) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin-ii-antikörper, systeme und verfahren
DK2962113T3 (da) 2013-02-28 2019-07-01 Biocare Medical Llc Systemer og fremgangsmåder med anti-p40-antistoffer
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
WO2014202089A2 (en) 2013-06-18 2014-12-24 Roskilde Universitet Variants of anti-freeze polypeptides
US9816997B2 (en) 2013-10-03 2017-11-14 Biocare Medical, Llc Anti-SOX10 antibody systems and methods
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2019152827A1 (en) * 2018-02-02 2019-08-08 AskGene Pharma, Inc. Novel antibody-drug conjugates (adc), methods of making, and methods of use thereof
CA3191184A1 (en) * 2020-08-28 2022-03-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Signal peptide for reducing end heterogeneity of heterologous polypeptide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
DE68926888T2 (de) * 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
DE3900534A1 (de) 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1991005856A1 (en) 1989-10-13 1991-05-02 Loyola University Of Chicago Chimeric monoclonal antibodies generated by trans-splicing
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate

Also Published As

Publication number Publication date
JPH09509054A (ja) 1997-09-16
WO1995021258A1 (en) 1995-08-10
EP0742830B1 (de) 2001-07-18
AU1690295A (en) 1995-08-21
DE69521789T2 (de) 2002-04-25
DE69521789D1 (de) 2001-08-23
EP0742830A1 (de) 1996-11-20
US6403769B1 (en) 2002-06-11
AU689214B2 (en) 1998-03-26
CA2182498A1 (en) 1995-08-10

Similar Documents

Publication Publication Date Title
ATE203274T1 (de) Fusionierte proteine die antikörper-teile und nicht-antikörper-teile enthalten
Shimizu et al. Physical interaction of Delta1, Jagged1, and Jagged2 with Notch1 and Notch3 receptors
Gandolfi et al. Characterization of proteins secreted by sheep oviduct epithelial cells and their function in embryonic development
Kurucz et al. Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv proteins from bacterial inclusion bodies
KR950700419A (ko) 단량체 및 이량체 항체-단편 융합 단백질(monomeric and dimeric antibody-fragment fusion proteins)
DK0804572T3 (da) Fusionsprotein omfattende bpTK7
UA40611C2 (uk) Імунокон'югат, спосіб його виготовлення, фармацевтична композиція
DE3382495D1 (de) Protein-a material und dessen herstellung.
CA2212702A1 (en) Mucosal vascular addressins and uses thereof
AU9135691A (en) G protein-coupled glutamate receptors
JP6598344B2 (ja) 環状ペプチドをタンパク質構造に提示させる超汎用法
DE69321580D1 (de) Car-rezeptoren und verwandte moleküle und entsprechende methoden
TW272197B (de)
KR930012827A (ko) 항 사람 IgE 모노클로날 항체
Iwata et al. Fibronectin from the ovary of the sea urchin, Pseudocentrotus depressus
DE59209839D1 (de) Monoklonalantikörper, Linker- und Beta-Glucuronidase enthaltende Fusionsproteine zur Prodrug-Aktivierung, ihre Herstellung und Verwendung
KR930701620A (ko) 재조합 dna 백터를 이용하여 인체 t-세포 리셉터 성분에 대한 단일 클론성 항체의 제조방법
JPS6468661A (en) Immunological method for determining isolated substance having hapten nature
CA2218755A1 (en) Monoclonal antibody to human beta 2 integrin alpha subunit
Peters et al. Binding and internalization of biotinylated interleukin-2 in human lymphocytes
Storch et al. A new and rapid method for immunoglobulin class and subclass determination of mouse monoclonal antibodies using a solid-phase immunoradiometric assay
WO2000017363A3 (en) Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
Clezardin et al. Cell attachment and fibrinogen binding properties of platelet and endothelial cell thrombospondin are not affected by structural differences in the 70 and 18 kDa protease‐resistant domains
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)
Wright et al. Testing of monoclonal antibody specificity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties